Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Offers €428 Million for Movetis To Expand Its GI Drug Portfolio

This article was originally published in The Pink Sheet Daily

Executive Summary

The J&J spin out, which raised more than €97 million in an IPO only eight months ago, would add to Shire's small but fast-growing gastrointestinal therapies franchise.

You may also be interested in...



On A Revenue Roll, Shire Takes Specialist Tactics To “Primary Care” Markets

Shire targets specialist segments of vast primary care populations, with focus on areas of unmet need.

Sofinnova Ventures' New $440M Eighth Fund Exceeds Expectations And Makes Adjustments

The firm wins higher commitments from limited partners, turning its health-care focus to late stage companies and forgoing high-tech investments.

Sofinnova Ventures' New $440M Eighth Fund Exceeds Expectations And Makes Adjustments

The firm wins higher commitments from limited partners, turning its health-care focus to late stage companies and forgoing high-tech investments.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel